Dear Madam, Dear Sir, Dear Investor,
It is with great pleasure that I welcome you to the website dedicated to investors.
Ikonisys' innovative approach is the automated detection, analysis and interpretation of rare and very rare cells. Ikonisys deploys a combination of equipment, software and reagents for automated diagnosis to improve the reporting of test results from medical laboratories.
Ikonisys' ambition is the early and accurate detection of cancerous diseases.
We thank you for your interest in our company,
- 30/09/2021 Ikonisys welcomes US sales director, accelerating its growth and expansion plans in the USA
- 06/09/2021 Initial results of a study, in collaboration with the uconn school of medicine, highlight the potential of ikonisys’ cell-based diagnostic platform in immuno-oncology
- 13/07/2021 Succes of Ikonisys' initial public offering on Euronext Growth® Paris
Ask us your questions
Subscribe to email alert